Soluble Expression of Recombinant Human CD137 Ligand in Escherichia Coli by Co-expression of Chaperones

Overview

Journal J Ind Microbiol Biotechnol

Publisher Oxford University Press

Specialty Biotechnology

Date 2011 Oct 15

PMID 21997275

Authors

Shuzhen Wang

Aimin Tan

Junfang Lv

Peng Wang

Xiaojin Yin

Yijun Chen

Affiliations

Soon will be listed here.

Abstract

CD137 ligand (CD137L) is a member of the tumor-necrosis factor superfamily that binds CD137 to provide positive co-stimulatory signals for T cells activation. Co-stimulation through CD137/CD137L has become one of the promising approaches for cancer therapy. Previous reports have shown that CD137L expressed in Escherichia coli resulted in inclusion bodies or low yield. In this study, the effects of five different chaperone teams on the soluble expression of recombinant human CD137L protein were explored and analyzed. The poor expression of CD137L in the cytoplasm of E. coli was improved significantly by co-expression of chaperone GroES-GroEL-Tf. After dual induction and affinity chromatography, purified recombinant CD137L was obtained at a yield of 3 mg protein per liter with purity greater than 98% from original undetectable level. Additionally, the purified recombinant CD137L could bind CD137-positive cells in a dose-dependent manner, markedly promote the growth of activated mice T cells, and elevate the release of IL-2. The present work provides an effective system for soluble expression of functional human co-stimulatory molecule CD137L, which will facilitate the clinical developments of recombinant protein drugs.

References

Peggs K, Quezada S, Allison J . Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin Exp Immunol. 2009; 157(1):9-19. PMC: 2710587. DOI: 10.1111/j.1365-2249.2009.03912.x. View

Schabowsky R, Elpek K, Madireddi S, Sharma R, Yolcu E, Bandura-Morgan L . A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity. Vaccine. 2009; 28(2):512-22. PMC: 2805442. DOI: 10.1016/j.vaccine.2009.09.127. View

Byun J, Kim D, Ahn B, Kwon B, Cho H . Crystallization and preliminary X-ray crystallographic study of the extracellular domain of the 4-1BB ligand, a member of the TNF family. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2006; 62(Pt 1):23-5. PMC: 2150926. DOI: 10.1107/S1744309105039242. View

Guo H, Jiang W, Liu W, Gao Y, Yang M, Zhou Y . Extracellular domain of 4-1BBL enhanced the antitumoral efficacy of peripheral blood lymphocytes mediated by anti-CD3 x anti-Pgp bispecific diabody against human multidrug-resistant leukemia. Cell Immunol. 2008; 251(2):102-8. DOI: 10.1016/j.cellimm.2008.04.006. View

Schwarz H, Valbracht J, Tuckwell J, von Kempis J, Lotz M . ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages. Blood. 1995; 85(4):1043-52. View

Foell J, Hewes B, Mittler R . T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity. Curr Cancer Drug Targets. 2007; 7(1):55-70. DOI: 10.2174/156800907780006841. View

Lynch D . The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev. 2008; 222:277-86. DOI: 10.1111/j.1600-065X.2008.00621.x. View

Won E, Cha K, Byun J, Kim D, Shin S, Ahn B . The structure of the trimer of human 4-1BB ligand is unique among members of the tumor necrosis factor superfamily. J Biol Chem. 2009; 285(12):9202-10. PMC: 2838339. DOI: 10.1074/jbc.M109.084442. View

Lin G, Liu Y, Ambagala T, Kwon B, Ohashi P, Watts T . Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice. PLoS One. 2010; 5(6):e11003. PMC: 2882368. DOI: 10.1371/journal.pone.0011003. View

10.

Rabu C, Quemener A, Jacques Y, Echasserieau K, Vusio P, Lang F . Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem. 2005; 280(50):41472-81. DOI: 10.1074/jbc.M506881200. View

11.

Alderson M, Smith C, Tough T, Armitage R, Falk B, Roux E . Molecular and biological characterization of human 4-1BB and its ligand. Eur J Immunol. 1994; 24(9):2219-27. DOI: 10.1002/eji.1830240943. View

12.

Meseck M, Huang T, Ma G, Wang G, Chen S, Woo S . A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J Immunother. 2011; 34(2):175-82. PMC: 3066178. DOI: 10.1097/CJI.0b013e318206dac1. View

13.

Nishihara K, Kanemori M, Kitagawa M, Yanagi H, Yura T . Chaperone coexpression plasmids: differential and synergistic roles of DnaK-DnaJ-GrpE and GroEL-GroES in assisting folding of an allergen of Japanese cedar pollen, Cryj2, in Escherichia coli. Appl Environ Microbiol. 1998; 64(5):1694-9. PMC: 106217. DOI: 10.1128/AEM.64.5.1694-1699.1998. View

14.

Ganguly S, Liu J, Pillai V, Mittler R, Amara R . Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. Vaccine. 2009; 28(5):1300-9. PMC: 2814905. DOI: 10.1016/j.vaccine.2009.11.020. View

15.

Erdile L, Smith D, Berd D . Whole cell ELISA for detection of tumor antigen expression in tumor samples. J Immunol Methods. 2001; 258(1-2):47-53. DOI: 10.1016/s0022-1759(01)00465-3. View

16.

Sharma R, Schabowsky R, Srivastava A, Elpek K, Madireddi S, Zhao H . 4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccines. Cancer Res. 2010; 70(10):3945-54. PMC: 2872136. DOI: 10.1158/0008-5472.CAN-09-4480. View

17.

de Marco A, Deuerling E, Mogk A, Tomoyasu T, Bukau B . Chaperone-based procedure to increase yields of soluble recombinant proteins produced in E. coli. BMC Biotechnol. 2007; 7:32. PMC: 1904446. DOI: 10.1186/1472-6750-7-32. View